OncLive SOSS

Authors

Tisch Cancer Institute

Latest:

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Eric A. Singer, MD

Latest:

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Advances in Targeted Therapy, Treatment Disparities Among Cancer Conference Talks

Targeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.

Phulong L. Mai, MD

Latest:

Dr. Mai on Barriers of Genetic Testing in CRC

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Meriem Mokhtech, MD

Latest:

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

John Crown, BCh, BAO, BSc, MD, MBA

Latest:

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Susan E. Waltz, PhD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Janet Abrahm, MD, FACP, FAAHPM

Latest:

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

Roisin E. O'Cearbhaill, MD

Latest:

Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.

Alexandre A. Jácome, MD, PhD

Latest:

Test for Summarization

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Milana Dolezal, MD, MSci

Latest:

Patient Profile 2: 3L Therapy for Triple-Positive mBC

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Anita D’Souza, MD

Latest:

Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL Amyloidosis

Anita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.

Danielle Krause, MD

Latest:

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Amgen Sponsored Content; OncLive Article with Dr. Edward S. Kim

Latest:

Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment Journey

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

Jason Westin MD, FACP

Latest:

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Patrick Pilie, MD

Latest:

Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPC

Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Latest:

Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part Sarcoma

Abdul Rafeh Naqash, MD, and Alice Chen, MD, discuss their phase 2 trial evaluating the efficacy of atezolizumab in patients with advanced alveolar soft part sarcoma.

Latest:

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Abdulrahman Sinno, MD

Latest:

Dr Sinno on Molecular Characterization in Endometrial Cancer

Abdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.

Jeanne Fourie Zirkelbach, PhD

Latest:

FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD

Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.